Ahmet Sami Bayram

Ahmet Sami Bayram

Auto-generated profile, based on publicly available information

Ahmet Sami Bayram

Department of Thoracic Surgery, Bursa Uludag University Faculty of Medicine, Bursa, Turkey

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Indian Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
EYEylem Yentürk
Eylem Yentürk
ABAhmet Sami Bayram
Ahmet Sami Bayram

14 July 2026 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
EYEylem Yentürk
Eylem Yentürk
ABAhmet Sami Bayram
Ahmet Sami Bayram

1 May 2004 in Indian Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
ABAhmet Sami Bayram
Ahmet Sami Bayram
MEMehmet Muharrem Erol
Mehmet Muharrem Erol
OSOzlem Saraydaroglu
Ozlem Saraydaroglu

3 September 2023 in The European Research Journal
Verified
Journal Article
Open access
PDF file
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
ECErdem Cubukcu
Erdem Cubukcu
ADadem deligonul
adem deligonul
BOBirol Ocak
Birol Ocak
HMHuseyin Melek
Huseyin Melek
TETürkkan Evrensel
Türkkan Evrensel
Objectives: Carcinoid tumors are rare neuroendocrine neoplasms of the lung. Although typical and atypical carcinoids have different clinical courses, most studies in the literature evaluate them together. Therefore, we aimed to investigate prognostic factors in patients with atypical carcinoids, excluding typical carcinoids. Methods: We included 32 patients with atypical carcinoids according to WHO 2021 criteria admitted to Uludag University Hospital. We retrospectively extracted the clinicopathological characteristics from electronic medical records. The log-rank tests were used to determine the prognostic factors on survival. Results: Median age was 57 (24-71) years. Pathological stages were as follows: stage I in 41%, II in 9%, III in 34%, and IV in 16%. Median Ki-67 index was 11% (1-50). Median follow-up time was 46.2 (0.7-184.2) months. 12-month and 48-month disease-free survival (DFS) rates were 92.3% and 79.2%, respectively. 12-month and 48-month overall survival (OS) rates were 93.8% and 86.2, respectively. Receiver operating characteristic curve analysis determined the Ki-67 cut-off as 12.5%. The log-rank test indicated that Ki-67 and stage were statistically significant prognostic factors for DFS and OS. The patients with a Ki-67 index lower than 12.5% had longer DFS and OS (p = 0.007 and p = 0.020, respectively). Conclusions: The Ki-67 index and 8th TNM staging have prognostic value on DFS and OS in patients with atypical carcinoids. Large-scale studies are needed to define the optimal cut-off value of Ki-67.

23 April 2025 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
SSSureyya Sarihan
Sureyya Sarihan
AMAybuke Tugce Metin
Aybuke Tugce Metin
ABAhmet Sami Bayram
Ahmet Sami Bayram
HMHuseyin Melek
Huseyin Melek
Purpose: The aim is to evaluate treatment outcomes and prognostic factors in patients with thymic epithelial tumor (TET) treated with radiotherapy (RT). Methods: Sixty-four patients were treated between 2000 and 2023. The median age was 52 years (20–83), and 81% of underwent R0 resection. The stage (s) distribution for I, II, III, and IV were 5%, 61%, 26%, and 8% by Masaoka-Koga and 63%, 11%, 17%, and 9% by TNM, respectively. WHO types A/AB/B/C and thymic neuroendocrine tumors were seen in 5%, 22%, 64%, 6%, and 3% of patients, respectively. The median RT dose was 5040 cGy (1620–6596). Survival was calculated from the beginning of RT. Results: The median follow-up was 70 months (1.5–268). The median time to recurrence was 30 months (6.5–106), seen in 23% of patients. Mean overall (OS), progression-free survival (PFS) and 5‑year local control were 141, 138 months, and 82.4%, respectively. In univariate analysis, the presence of organ invasion and TNM stage were significant as new prognostic factors for survival ( p < 0.05). In multivariate analysis, the high-risk group (B2/B3/C) and another surgical center ( p < 0.05) for OS, and KPS ≤ 80, thymic carcinoma, and Masaoka-Koga sIII-IV ( p < 0.05) for PFS were identified as unfavorable prognostic factors. Conclusion: Recurrence in TET can occur over a longer period. In this study, 5‑year local control of 82.4% was achieved. The prognostic importance of KPS, histology, Masaoka-Koga stage, risk group, and surgical center was demonstrated. Advances in the diagnosis, staging, and treatment of TET will enable more personalized treatment.

1 August 2021 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
RKReyhan Kasab
Reyhan Kasab
PEPınar Eser
Pınar Eser
YTYağmur TUNÇBİLEKLİ
Yağmur TUNÇBİLEKLİ
SBSami Bayram
Sami Bayram
MTM Özgür Taşkapilioğlu
M Özgür Taşkapilioğlu
Hidrosefali, beyin omurilik sıvısında artış ile seyreden, serebral ventriküllerde genişlemeye ve serebral kortekste incelmeye neden olan artmış intrakraniyal basınç ile karakterize yaygın bir nöroşirurjikal hastalıktır. Hidrosefalinin yönetiminde en sık kullanılan tedavi yöntemi ventriküloperitoneal şanttır. Şant işlemi sonrası daha çok mekanik obstrüksiyonlar ve enfeksiyonlar görülmektedir. Torasik migrasyon oldukça nadir görülür fakat görüldüğü zaman ivedilikle müdahale edilmesi gereken bir tablodur.